Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization.

Details

Ressource 1Download: BIB_B7FB71C24DD8.P001.pdf (1931.93 [Ko])
State: Public
Version: author
Serval ID
serval:BIB_B7FB71C24DD8
Type
Article: article from journal or magazin.
Collection
Publications
Title
Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization.
Journal
Neoplasia
Author(s)
Nunez-Cruz S., Gimotty P.A., Guerra M.W., Connolly D.C., Wu Y.Q., DeAngelis R.A., Lambris J.D., Coukos G., Scholler N.
ISSN
1476-5586 (Electronic)
ISSN-L
1476-5586
Publication state
Published
Issued date
2012
Volume
14
Number
11
Pages
994-1004
Language
english
Notes
Publication types: Journal Article Publication Status: ppublish
Abstract
Complement activation plays a critical role in controlling inflammatory responses. To assess the role of complement during ovarian cancer progression, we crossed two strains of mice with genetic complement deficiencies with transgenic mice that develop epithelial ovarian cancer (TgMISIIR-TAg). TgMISIIR-TAg mice fully or partially deficient for complement factor 3 (C3) (Tg(+)C3(KO) and Tg(+)C3(HET), respectively) or fully deficient for complement factor C5a receptor (C5aR) (Tg(+)C5aR(KO)) develop either no ovarian tumors or tumors that were small and poorly vascularized compared to wild-type littermates (Tg(+)C3(WT), Tg(+)C5aR(WT)). The percentage of tumor infiltrating immune cells in Tg(+)C3(HET) tumors compared to Tg(+)C3(WT) controls was either similar (macrophages, B cells, myeloid-derived suppressor cells), elevated (effector T cells), or decreased (regulatory T cells). Regardless of these ratios, cytokine production by immune cells taken from Tg(+)C3(HET) tumors was reduced on stimulation compared to Tg(+)C3(WT) controls. Interestingly, CD31(+) endothelial cell (EC) function in angiogenesis was significantly impaired in both C3(KO) and C5aR(KO) mice. Further, using the C5aR antagonist PMX53, tube formation of ECs was shown to be C5a-dependent, possibly through interactions with the VEGF(165) but not VEGF(121) isoform. Finally, the mouse VEGF(164) transcript was underexpressed in C3(KO) livers compare to C3(WT) livers. Thus, we conclude that complement inhibition blocks tumor outgrowth by altering EC function and VEGF(165) expression.
Keywords
Animals, Cell Transformation, Neoplastic/genetics, Cell Transformation, Neoplastic/immunology, Complement Activation/immunology, Complement C3/deficiency, Complement C5a/antagonists & inhibitors, Complement C5a/immunology, Complement System Proteins/drug effects, Complement System Proteins/genetics, Endothelial Cells/drug effects, Endothelial Cells/immunology, Female, Humans, Lymphocytes, Tumor-Infiltrating/immunology, Male, Mice, Mice, Transgenic, Neovascularization, Pathologic/immunology, Ovarian Neoplasms/blood supply, Ovarian Neoplasms/genetics, Peptides, Cyclic/pharmacology, Protein Isoforms, Vascular Endothelial Growth Factor A/metabolism
Pubmed
Web of science
Create date
14/10/2014 11:42
Last modification date
20/08/2019 15:26
Usage data